In contrast, stem cells were highly resistant to the EGFR inhibitor erlotinib, a widely used drug for lung cancer, and the ERK inhibitor PD98059, which is active against a variety of cancer cell lines (Figure3(b), dashed lines). The gene discussed is EGFR; the disease is lung carcinoma.